(Q36027509)

11 August 2017

1 reference

title

The tuberculosis vaccine challenge (English)

1 reference

11 August 2017

0 references

Michael J Brennan

1

1 reference

11 August 2017

publication date

1 January 2005

1 reference

11 August 2017

1 reference

11 August 2017

volume

85

1 reference

11 August 2017

issue

1-2

1 reference

11 August 2017

page(s)

7-12

1 reference

Variation in protection by BCG: implications of and for heterologous immunity

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2004.09.001

Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2004.09.001

Boosting vaccine for tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2004.09.001

Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2004.09.001

Prospects for a better vaccine against tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2004.09.001

A pantothenate auxotroph of Mycobacterium tuberculosis is highly attenuated and protects mice against tuberculosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2004.09.001

Attenuation of and protection induced by a leucine auxotroph of Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2004.09.001

Mycobacterium bovis Bacille Calmette-Guérin strains secreting listeriolysin of Listeria monocytogenes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2004.09.001

Propelling novel vaccines directed against tuberculosis through the regulatory process

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2004.09.001

Recombinant bacillus Calmette-Guérin as a potential vector for preventive HIV type 1 vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2004.09.001

The regulation of DNA vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2004.09.001

BCG: the challenge continues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2004.09.001

A re-examination of the variations in the efficacy of BCG vaccination against tuberculosis in clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2004.09.001

Mycobacterial antigens exacerbate disease manifestations in Mycobacterium tuberculosis-infected mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2004.09.001

Pulmonary necrosis resulting from DNA vaccination against tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2004.09.001

Design of the Brazilian BCG-REVAC trial against tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2004.09.001

Revaccination of neonatal calves with Mycobacterium bovis BCG reduces the level of protection against bovine tuberculosis induced by a single vaccination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2004.09.001

The in vitro evolution of BCG vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2004.09.001

Immune responses stimulated by percutaneous and intradermal bacille Calmette-Guérin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2004.09.001

Danish bacille Calmette-Guérin vaccine-induced disease in human immunodeficiency virus-infected children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2004.09.001

Immunization with a DNA vaccine cocktail protects mice lacking CD4 cells against an aerogenic infection with Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2004.09.001

Global Forum on TB Vaccine Research and Development. World Health Organization, June 7-8 2001, Geneva

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2004.09.001

Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guérin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2004.09.001

Two novel T cell epitope prediction algorithms based on MHC-binding motifs; comparison of predicted and published epitopes from Mycobacterium tuberculosis and HIV protein sequences.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2004.09.001

Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and esat-6.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2004.09.001

Vaccination against tuberculosis by DNA injection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2004.09.001

DNA vaccine combinations expressing either tissue plasminogen activator signal sequence fusion proteins or ubiquitin-conjugated antigens induce sustained protective immunity in a mouse model of pulmonary tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2004.09.001

New vaccines for the prevention of tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2004.09.001

10.1016/J.TUBE.2004.09.001

7 January 2021

Identifiers

DOI

1 reference

11 August 2017

1 reference